KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

TherapeuticsMD (TXMD) Debt to Equity (2018 - 2022)

TherapeuticsMD filings provide 8 years of Debt to Equity readings, the most recent being -$1.94 for Q3 2022.

  • On a quarterly basis, Debt to Equity rose 40.44% to -$1.94 in Q3 2022 year-over-year; TTM through Sep 2022 was -$1.94, a 40.44% increase, with the full-year FY2021 number at -$2.01, down 4.91% from a year prior.
  • Debt to Equity hit -$1.94 in Q3 2022 for TherapeuticsMD, up from -$3.48 in the prior quarter.
  • In the past five years, Debt to Equity ranged from a high of $23.98 in Q2 2019 to a low of -$19.41 in Q1 2021.
  • Median Debt to Equity over the past 5 years was -$1.98 (2021), compared with a mean of -$0.43.
  • The widest YoY moves for Debt to Equity: up 2711.34% in 2019, down 1777.3% in 2019.
  • TherapeuticsMD's Debt to Equity stood at $0.75 in 2018, then skyrocketed by 2711.34% to $21.15 in 2019, then plummeted by 109.06% to -$1.92 in 2020, then fell by 4.91% to -$2.01 in 2021, then rose by 3.57% to -$1.94 in 2022.
  • The last three reported values for Debt to Equity were -$1.94 (Q3 2022), -$3.48 (Q2 2022), and -$1.44 (Q1 2022) per Business Quant data.